Ares Life Sciences is an investment partnership established in 2008 with the backing of the Bertarelli family. Managed by an experienced team of healthcare executives and focused on long-term value creation, the partnership invests exclusively in revenue-generating life science companies.

Ares Life Sciences focuses on the following sub-sectors:

  • Pharmaceuticals
  • Biotech
  • Medical technologies
  • Healthcare services

 


NEWS

16.05.2013
Stallergenes et DBV Technologies s’associent pour développer des traitements innovants contre les allergies respiratoires Ce partenariat vise à développer, à partir du patch mis au point par DBV, Viaskin®, une nouvelle approche dans la désensibilisation des allergies respiratoires ANTONY et BAGNEUX, le 16 mai 2013 ‐ DBV Technologies (Euronext : DBV – Code ISIN : FR0010417345), créateur du Viaskin®, une nouvelle référence dans le traitement de l’allergie, et Stallergenes S. (...) Learn more +

13.05.2013
Santhera's Shareholders Support Business Continuation and Evaluation of Strategic Options Liestal, Switzerland, May 13, 2013 - Santhera Pharmaceuticals (SIX: SANN) announced today that, at its Annual Shareholders' Meeting, a large majority of shareholders represented approved all proposals by the Board of Directors. (...) Learn more +

Av. Giuseppe-Motta 31-33
CH-1211 Geneva
T +41 58 944 04 00
Email info@areslifesciences.com